Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort
Open Access
- 20 January 2009
- journal article
- Published by Springer Science and Business Media LLC in BMC Gastroenterology
- Vol. 9 (1), 6
- https://doi.org/10.1186/1471-230x-9-6
Abstract
Irritable bowel syndrome (IBS) is a common disorder that affects 10–15% of the population. Although characterised by a lack of reliable biological markers, the disease state is increasingly viewed as a disorder of the brain-gut axis. In particular, accumulating evidence points to the involvement of both the central and peripheral serotonergic systems in disease symptomatology. Furthermore, altered tryptophan metabolism and indoleamine 2,3-dioxygenase (IDO) activity are hallmarks of many stress-related disorders. The kynurenine pathway of tryptophan degradation may serve to link these findings to the low level immune activation recently described in IBS. In this study, we investigated tryptophan degradation in a male IBS cohort (n = 10) and control subjects (n = 26). Plasma samples were obtained from patients and healthy controls. Tryptophan and its metabolites were measured by high performance liquid chromatography (HPLC) and neopterin, a sensitive marker of immune activation, was measured using a commercially available ELISA assay. Both kynurenine levels and the kynurenine:tryptophan ratio were significantly increased in the IBS cohort compared with healthy controls. Neopterin was also increased in the IBS subjects and the concentration of the neuroprotective metabolite kynurenic acid was decreased, as was the kynurenic acid:kynurenine ratio. These findings suggest that the activity of IDO, the immunoresponsive enzyme which is responsible for the degradation of tryptophan along this pathway, is enhanced in IBS patients relative to controls. This study provides novel evidence for an immune-mediated degradation of tryptophan in a male IBS population and identifies the kynurenine pathway as a potential source of biomarkers in this debilitating condition.Keywords
This publication has 28 references indexed in Scilit:
- Evidence of an enhanced central 5HT response in irritable bowel syndrome and in the rat maternal separation modelNeurogastroenterology & Motility, 2008
- 5-HT and the brain–gut axis: opportunities for pharmacologic interventionExpert Opinion on Investigational Drugs, 2007
- Tryptophan metabolism in the central nervous system: medical implicationsExpert Reviews in Molecular Medicine, 2006
- Review article: modulation of the brain–gut axis as a therapeutic approach in gastrointestinal diseaseAlimentary Pharmacology & Therapeutics, 2006
- Hypothalamic-Pituitary-Gut Axis Dysregulation in Irritable Bowel Syndrome: Plasma Cytokines as a Potential Biomarker?Gastroenterology, 2006
- Acute tryptophan depletion affects brain-gut responses in irritable bowel syndrome patients and controlsGut, 2004
- Role of serotonin in the pathophysiology of the irritable bowel syndromeBritish Journal of Pharmacology, 2004
- Postinfectious irritable bowel syndromeGastroenterology, 2003
- Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical OpportunitiesThe Journal of pharmacology and experimental therapeutics, 2002
- Serotoninergic neuroenteric modulatorsThe Lancet, 2001